Substance
ID:449847
Names and Identifiers
IUPAC name
4-(2-{[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
Synonyms
InofrexDobutrexDobutamine hydrochloride
IUPAC Traditional name
4-(2-{[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
Registration numbers
CAS Number
Properties
Product Information
Application(s)
Used in the treatment of heart failure and cardiogenic shock
Sympathomimetic drug
Pharmacology Properties
Mechanism of Action
Stimulation of beta1 receptors of the sympathetic nervous system
Molecule Details
No Data Available
Click here to submit data
Molecular Spectra
No Data Available
Click here to submit data
References
• Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology.
• Parker K, Brunton L, Goodman LS, Blumenthal D, Buxton I (2008). Goodman & Gilman's manual of pharmacology and therapeutics. McGraw-Hill Medical. pp. 159. ISBN 0-07-144343-6.
• Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 6. ISBN 1-59541-101-1.
• Am. J. Respir. Crit. Care Med. 156 (2 Pt 1): 438?4. PMID 9279221
• Tuttle RR, Mills J (January 1975). "Dobutamine: development of a new catecholamine to selectively increase cardiac contractility". Circ Res 36 (1): 185?6. PMID 234805.
• Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA (1997). "Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation".